Search results for " thromboembolism"

showing 10 items of 158 documents

Anti-Factor Xa levels correlate with recurrent venous thromboembolism and clinically relevant bleeding in patients receiving low-molecular-weight hep…

2019

Background: The aim of our study was to investigate whether anti-Xa levels assessed in selected groups of LMWH-treated patients with VTE correlate with the risk of developing thromboembolic or bleeding complications. Methods: Retrospective study, in adult patients treated with anti-Xa-adjusted LMWH analysing the association between anti-Xa activity and recurrent VTE or bleeding. Primary outcomes were symptomatic fatal or nonfatal objectively diagnosed VTE and clinically relevant bleeding (ISTH criteria). Results: From 2007-2017, 192 patients were recruited. Mean age was 62 (SD 18) years and 48% were men. Indications for anti-Xa monitoring were: VTE recurrence under anticoagulation (20.8%), …

medicine.medical_specialtyAdult patientsmedicine.drug_classbusiness.industryLow molecular weight heparinMean ageRetrospective cohort studyInternal medicineRelative riskmedicineIn patientcardiovascular diseasesAnti factor xabusinessVenous thromboembolismPulmonary embolism
researchProduct

Derivation and validation of a novel bleeding risk score for elderly patients with venous thromboembolism on extended anticoagulation

2017

SummaryExisting clinical scores do not perform well in predicting bleeding in elderly patients with acute venous thromboembolism (VTE). We sought to derive an easy-to-use clinical score to help physicians identify elderly patients with VTE who are at high-risk of bleeding during extended anticoagulation (>3 months). Our derivation sample included 743 patients aged ≥65 years with VTE who were enrolled in a prospective multicenter cohort study. All patients received extended anticoagulation with vitamin K antagonists. We derived our score using competing risk regression, with the time to a first major bleeding up to 36 months of extended anticoagulation as the outcome, and 17 candidate var…

medicine.medical_specialtyAnemia2720 Hematology610 Medicine & health030204 cardiovascular system & hematology03 medical and health sciencesAnticoagulation0302 clinical medicineElderlyInternal medicineAnticoagulation; Bleeding risk; Elderly; HematologyBleeding riskmedicineDerivation030212 general & internal medicineInternal validation610 Medicine & healthddc:616Framingham Risk Scorebusiness.industry10031 Clinic for AngiologyCancerHematologymedicine.diseaseSurgery10209 Clinic for CardiologybusinessVenous thromboembolismMajor bleeding360 Social problems & social servicesCohort study
researchProduct

Combined use of antifibrinolytics and activated prothrombin complex concentrate (aPCC) is not related to thromboembolic events in patients with acqui…

2019

Antifibrinolytics combined with aPCC are not routinely administered to patients with acquired hemophilia A due to increased thrombotic risk. This association normalizes clot stability, and improves the efficacy of therapy, but can increase the risk of severe side effects. Due to these premises it has always raised doubts and perplexities in the clinics. We now report the data of the "FEIBA® on acquired haemophilia A Italian Registry (FAIR Registry)", a retrospective-prospective study that included 56 patients. This is the first study that assessed the clinical response of the combination of aPCC and antifibrinolytic agents in patients with acquired haemophilia A. A total of 101 acute bleeds…

medicine.medical_specialtyAntifibrinolyticmedicine.drug_classHemorrhage030204 cardiovascular system & hematologyHemophilia APremises03 medical and health sciences0302 clinical medicineDrug TherapyThromboembolismAntifibrinolytic agentInternal medicineActivated prothrombin complex concentrateAcquired haemophiliaThromboembolic riskHumansMedicineIn patientRegistries030212 general & internal medicineAcquired haemophilia AHematologybusiness.industryHematologyAcquired haemophilia A; Activated prothrombin complex concentrate; Antifibrinolytics; Thromboembolic risk; Antifibrinolytic Agents; Blood Coagulation Factors; Cardiovascular Diseases; Drug Therapy Combination; Hemophilia A; Hemorrhage; Humans; Registries; ThromboembolismAntifibrinolytic AgentsBlood Coagulation FactorsClinical trialTolerabilityCardiovascular DiseasesCombinationAntifibrinolyticDrug Therapy CombinationAntifibrinolyticsCardiology and Cardiovascular Medicinebusiness
researchProduct

Aspirin After Oral Anticoagulants for Prevention of Recurrence in Patients with Unprovoked Venous Thromboembolism. the Warfasa STUDY

2011

Abstract Abstract 543 Background A recurrence occurs in 15–20% of patients with unprovoked venous thromboembolism (VTE) in the two years after the withdrawal of oral anticoagulant treatment. Extending anticoagulant treatment is effective but associated with increased bleeding risk. We assessed the efficacy and safety of aspirin for the prevention of VTE recurrence after a conventional course of oral anticoagulation. Methods Warfasa was an investigator-initiated double-blind randomized placebo-controlled event-driven study. Patients with a first-ever unprovoked VTE who had completed 6–12 months of oral anticoagulant treatment were randomized to receive aspirin, 100 mg daily, or placebo for a…

medicine.medical_specialtyAspirinbusiness.industryIncidence (epidemiology)ImmunologyHazard ratioCell BiologyHematologyPlaceboRelapse preventionBiochemistrySurgeryInternal medicinemedicineIn patientbusinessVenous thromboembolismOral anticoagulationmedicine.drugBlood
researchProduct

Mean platelet volume in arterial and venous thrombotic disorders

2020

Abstract The mean platelet volume (MPV) is an easy, rapid and inexpensive laboratory parameter which basically mirrors platelet size. Due to the essential role of platelets in hemostasis, many studies have assessed the MPV value in patients with arterial and venous thrombotic disorders. These have then been summarized in some interesting meta-analyses and recent studies that will be discussed in this narrative review. Taken together, the currently available evidence suggests that the MPV may be substantially increased in concomitance with acute episodes of coronary artery disease, venous thromboembolism, portal vein thrombosis, stroke, erectile dysfunction and preeclampsia. In many of these…

medicine.medical_specialtyClinical Biochemistryvenous thromboembolism030204 cardiovascular system & hematologyCoronary artery disease03 medical and health sciences0302 clinical medicineInternal medicineMedical technologymedicineDiscrete Mathematics and CombinatoricsPlateletR855-855.5Mean platelet volumethrombosismean platelet volumebusiness.industryBiochemistry (medical)medicine.diseaseThrombosis030220 oncology & carcinogenesisplateletsCardiologycoronary artery disease; mean platelet volume; platelets; thrombosis; venous thromboembolismbusinessVenous thromboembolismcoronary artery disease
researchProduct

Thrombosis and thromboembolism related to COVID‐19: A clarion call for obtaining solid estimates from large‐scale multicenter data

2020

Abstract The clinical spectrum of coronavirus disease 2019 (COVID‐19) is wide, ranging from minor, nonspecific symptoms to severe pneumonia, acute respiratory distress syndrome, multiorgan involvement, and shock. In severe cases, the acute systemic inflammatory response, coagulation activation, and diffuse endothelial damage may, in combination with hypoxia, immobilization, and underlying risk factors, result in potentially life‐threatening venous and arterial thrombotic events. The first data from single‐center retrospective studies suggest that thrombotic events are a key aspect of COVID‐19‐associated morbidity and mortality. We have planned and will be launching the COvid REgistry on THR…

medicine.medical_specialtyCoronavirus disease 2019 (COVID-19)Hospitalized patientsvenous thromboembolism610 Medicine & healthAcute respiratory distressregistrymedicine.disease_causeSARS‐CoV‐2COVID‐19Internal medicineMedicineIn patientthrombosisCoronavirusCOVIDbusiness.industryForumlcsh:RC633-647.510031 Clinic for AngiologyRetrospective cohort studyHematologylcsh:Diseases of the blood and blood-forming organsHypoxia (medical)medicine.diseaseThrombosismedicine.symptombusinessResearch and Practice in Thrombosis and Haemostasis
researchProduct

Leisure-time cross-country skiing and the risk of venous thromboembolism: A prospective cohort study

2020

[No abstract]

medicine.medical_specialtyCross countryEpidemiologybusiness.industryLeisure timeEmergency medicineMedicineCardiology and Cardiovascular MedicineProspective cohort studybusinessVenous thromboembolismEuropean Journal of Preventive Cardiology
researchProduct

A multicenter real‐life study on anticoagulant treatment with direct oral anticoagulants in patients with P h‐negative myeloproliferative neoplasms

2020

NA

medicine.medical_specialtyDOACbusiness.industrymyeloproliferative neoplasmvenous thromboembolismMEDLINEdirect oral anticoagulantAtrial fibrillationHematologymedicine.diseasePhiladelphia chromosomeClinical trialText miningAnticoagulant therapyInternal medicineMedicineLife studybusinessMyeloproliferative neoplasmatrial fibrillation.American Journal of Hematology
researchProduct

Impact of sex, age, and risk factors for venous thromboembolism on the initial presentation of first isolated symptomatic acute deep vein thrombosis

2019

Abstract Background and aims Sex-specific differences exist for the initial presentation of acute venous thromboembolism (VTE): men are more likely to present with proximal deep vein thrombosis (DVT) in the lower limbs (versus pulmonary embolism [PE] or isolated distal DVT [IDDVT]) than women. We studied in detail the influence of sex, age, and VTE risk factors on the initial presentation of IDDVT versus proximal DVT. Methods A total of 24,911 patients with a first episode of objectively diagnosed acute symptomatic lower-limb DVT (without symptomatic PE) were enrolled in RIETE (years 2000–2017) and included in the present analysis. Results A total of 4266 (17.1%) patients had IDDVT. No tren…

medicine.medical_specialtyEpidemiologyDeep vein030204 cardiovascular system & hematologyDistal DVT03 medical and health sciences0302 clinical medicineDeep vein thrombosiDeep vein thrombosisInternal medicineEpidemiologymedicinecardiovascular diseasesFirst episodePregnancyProvoking risk factorsbusiness.industryCancerHematologymedicine.diseaseThrombosisPathophysiologyPulmonary embolismmedicine.anatomical_structureProvoking risk factor030220 oncology & carcinogenesisSexbusinessVenous thromboembolism
researchProduct

Physical activity and risk of venous thromboembolism: systematic review and meta-analysis of prospective cohort studies

2019

The inverse association between physical activity and arterial thrombotic disease is well established. Evidence on the association between physical activity and venous thromboembolism (VTE) is divergent. We conducted a systematic review and meta-analysis of published observational prospective cohort studies evaluating the associations of physical activity with VTE risk. MEDLINE, Embase, Web of Science, and manual search of relevant bibliographies were systematically searched until 26 February 2019. Extracted relative risks (RRs) with 95% confidence intervals (CIs) for the maximum versus minimal amount of physical activity groups were pooled using random effects meta-analysis. Twelve article…

medicine.medical_specialtyEpidemiologyvenous thromboembolismphysical activity030204 cardiovascular system & hematologyliikunta03 medical and health sciences0302 clinical medicinesystematic reviewRisk FactorsInternal medicineEpidemiologymedicinecohort studyHumans030212 general & internal medicineRisk factorProspective cohort studykohorttitutkimusExercisebusiness.industryPhysical activitymeta-analyysiPublication biasriskitekijätVenous Thromboembolismmeta-analysisrisk factorMeta-analysisRelative risksydän- ja verisuonitauditSystematic reviewRisk factortromboosibusinessCohort studyBody mass indexfyysinen aktiivisuusCohort studyMeta-AnalysisEuropean Journal of Epidemiology
researchProduct